284 related articles for article (PubMed ID: 18524871)
1. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.
Weiss HM; Fresneau M; Moenius T; Stuetz A; Billich A
Drug Metab Dispos; 2008 Sep; 36(9):1812-8. PubMed ID: 18524871
[TBL] [Abstract][Full Text] [Related]
2. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin.
Meingassner JG; Aschauer H; Stuetz A; Billich A
Exp Dermatol; 2005 Oct; 14(10):752-7. PubMed ID: 16176283
[TBL] [Abstract][Full Text] [Related]
3. Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro.
Gschwind HP; Waldmeier F; Zollinger M; Schweitzer A; Grassberger M
Eur J Pharm Sci; 2008 Jan; 33(1):9-19. PubMed ID: 17996430
[TBL] [Abstract][Full Text] [Related]
4. Pimecrolimus -- an anti-inflammatory drug targeting the skin.
Grassberger M; Steinhoff M; Schneider D; Luger TA
Exp Dermatol; 2004 Dec; 13(12):721-30. PubMed ID: 15560755
[TBL] [Abstract][Full Text] [Related]
5. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis.
Bos JD
Eur J Dermatol; 2003; 13(5):455-61. PubMed ID: 14693489
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
Draelos Z; Nayak A; Pariser D; Shupack JL; Chon K; Abrams B; Paul CF
J Am Acad Dermatol; 2005 Oct; 53(4):602-9. PubMed ID: 16198779
[TBL] [Abstract][Full Text] [Related]
7. The role of pimecrolimus cream 1% (Elidel)) in managing adult atopic eczema.
Meurer M; Lubbe J; Kapp A; Schneider D
Dermatology; 2007; 215 Suppl 1():18-26. PubMed ID: 18174690
[TBL] [Abstract][Full Text] [Related]
8. Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation.
Lerche CM; Philipsen PA; Poulsen T; Wulf HC
Exp Dermatol; 2009 Mar; 18(3):246-51. PubMed ID: 19183401
[TBL] [Abstract][Full Text] [Related]
9. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
Werfel T
J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820
[TBL] [Abstract][Full Text] [Related]
10. Pimecrolimus in dermatology: atopic dermatitis and beyond.
Gisondi P; Ellis CN; Girolomoni G
Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
[TBL] [Abstract][Full Text] [Related]
11. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin.
Ständer S; Ständer H; Seeliger S; Luger TA; Steinhoff M
Br J Dermatol; 2007 May; 156(5):1020-6. PubMed ID: 17388925
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
[TBL] [Abstract][Full Text] [Related]
13. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
Schneeweiss S; Doherty M; Zhu S; Funch D; Schlienger RG; Fernandez-Vidaurre C; Seeger JD
Dermatology; 2009; 219(1):7-21. PubMed ID: 19293564
[TBL] [Abstract][Full Text] [Related]
14. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients.
Doelker L; Tran C; Gkomouzas A; Grand D; Sorg O; Saurat JH; Lübbe J
Exp Dermatol; 2006 May; 15(5):342-6. PubMed ID: 16630073
[TBL] [Abstract][Full Text] [Related]
15. Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity.
Stuetz A; Grassberger M; Meingassner JG
Semin Cutan Med Surg; 2001 Dec; 20(4):233-41. PubMed ID: 11770910
[TBL] [Abstract][Full Text] [Related]
16. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis.
Undre NA; Moloney FJ; Ahmadi S; Stevenson P; Murphy GM
Br J Dermatol; 2009 Mar; 160(3):665-9. PubMed ID: 19076975
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.
Billich A; Aschauer H; Aszódi A; Stuetz A
Int J Pharm; 2004 Jan; 269(1):29-35. PubMed ID: 14698574
[TBL] [Abstract][Full Text] [Related]
18. [Prescription of topical immunomodulators].
Rosenzweig M
Ugeskr Laeger; 2009 Aug; 171(35):2472-6. PubMed ID: 19732534
[TBL] [Abstract][Full Text] [Related]
19. Topical pimecrolimus in the treatment of vitiligo.
Boone B; Ongenae K; Van Geel N; Vernijns S; De Keyser S; Naeyaert JM
Eur J Dermatol; 2007; 17(1):55-61. PubMed ID: 17324829
[TBL] [Abstract][Full Text] [Related]
20. [Topical pimecrolimus and tacrolimus and the risk of cancer].
Sánchez-Pérez J
Actas Dermosifiliogr; 2007 Jun; 98(5):312-7. PubMed ID: 17555673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
